Gary D. Glick
Gründer bei IFM Therapeutics LLC
Profil
Gary D.
Glick was the founder of Lycera Corp.
(founded in 2006) where he served as the Chief Science Officer & Director from 2010 to 2011.
He is also the founder of IFM Therapeutics LLC (founded in 2015) where he currently holds the position of Executive Chairman.
Additionally, he is the founder of First Wave Bio, Inc. (founded in 2015) and currently serves as the Chief Executive Officer & Director.
Dr. Glick is currently the President & Director of Novartis Inflammasome Research, Inc. He also holds director positions at IFM Cinque, Inc., IFM Continua, Inc., IFM Quattro, Inc., and serves as the President & Director of IFM Due, Inc. Furthermore, he is a Senior Advisor at Abingworth Management, Inc. and a Counselor-Biological Chemistry Division at the American Chemical Society.
In the past, Dr. Glick served as the Director-Advisory Board at the National Institutes of Health.
He was also a Faculty Member at the University of Michigan in 2013 and an Advisor at Delin Ventures Ltd.Dr. Glick obtained his doctorate degree from The Trustees of Columbia University in The City of New York in 1988.
Dr. Glick is also the founder of Scorpion Therapeutics, Inc., Odyssey Therapeutics, Inc...
Aktive Positionen von Gary D. Glick
| Unternehmen | Position | Beginn |
|---|---|---|
American Chemical Society
 American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Corporate Officer/Principal | 22.03.2011 |
IFM Therapeutics LLC
 IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology IFM Therapeutics LLC engages in the development and transformation of immunotherapy for patients with serious diseases. It focuses on developing small molecule drugs that target the innate immune system. The company was founded by Gary D. Glick, Luigi Franchi, Matthias Geyer, Eicke Latz, and Anthony W. Opipari, Jr. in 2015 and is headquartered in Boston, MA. | Gründer | 01.01.2015 |
First Wave Bio, Inc.
 First Wave Bio, Inc. Miscellaneous Commercial ServicesCommercial Services First Wave Bio, Inc. develops novel therapeutics for the treatment of inflammatory bowel disease. The company was founded by Gary D. Glick, Anthony W. Opipari, Luigi Franchi in 2015 and is headquartered in New York, NY. | Gründer | 01.01.2015 |
IFM Quattro, Inc.
 IFM Quattro, Inc. Miscellaneous Commercial ServicesCommercial Services IFM Quattro, Inc. is a biotechnology company. The company is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | - |
IFM Cinque, Inc.
 IFM Cinque, Inc. Miscellaneous Commercial ServicesCommercial Services IFM Cinque, Inc. is a biotechnology company. The company is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | - |
IFM Continua, Inc.
 IFM Continua, Inc. BiotechnologyHealth Technology IFM Continua, Inc. engages in the provision of biotechnology services. The company is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | - |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Gründer | - |
Abingworth Management, Inc.
 Abingworth Management, Inc. Investment ManagersFinance Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA. | Berater | - |
Ehemalige bekannte Positionen von Gary D. Glick
| Unternehmen | Position | Ende |
|---|---|---|
Delin Ventures Ltd.
 Delin Ventures Ltd. Investment ManagersFinance Delin Ventures Ltd. (Delin Ventures) is a venture capital firm founded in 2013 by Igor Linshits. The firm headquartered in London, United Kingdom. | Berater | - |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Gary D. Glick
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |
American Chemical Society
American Chemical Society Miscellaneous Commercial ServicesCommercial Services American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC. | Commercial Services |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Abingworth Management, Inc.
Abingworth Management, Inc. Investment ManagersFinance Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA. | Finance |
IFM Therapeutics LLC
IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology IFM Therapeutics LLC engages in the development and transformation of immunotherapy for patients with serious diseases. It focuses on developing small molecule drugs that target the innate immune system. The company was founded by Gary D. Glick, Luigi Franchi, Matthias Geyer, Eicke Latz, and Anthony W. Opipari, Jr. in 2015 and is headquartered in Boston, MA. | Health Technology |
Delin Ventures Ltd.
Delin Ventures Ltd. Investment ManagersFinance Delin Ventures Ltd. (Delin Ventures) is a venture capital firm founded in 2013 by Igor Linshits. The firm headquartered in London, United Kingdom. | Finance |
Novartis Inflammasome Research, Inc.
 Novartis Inflammasome Research, Inc. Pharmaceuticals: MajorHealth Technology Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA. | Health Technology |
First Wave Bio, Inc.
First Wave Bio, Inc. Miscellaneous Commercial ServicesCommercial Services First Wave Bio, Inc. develops novel therapeutics for the treatment of inflammatory bowel disease. The company was founded by Gary D. Glick, Anthony W. Opipari, Luigi Franchi in 2015 and is headquartered in New York, NY. | Commercial Services |
IFM Cinque, Inc.
IFM Cinque, Inc. Miscellaneous Commercial ServicesCommercial Services IFM Cinque, Inc. is a biotechnology company. The company is headquartered in Boston, MA. | Commercial Services |
IFM Continua, Inc.
IFM Continua, Inc. BiotechnologyHealth Technology IFM Continua, Inc. engages in the provision of biotechnology services. The company is headquartered in Boston, MA. | Health Technology |
IFM Quattro, Inc.
IFM Quattro, Inc. Miscellaneous Commercial ServicesCommercial Services IFM Quattro, Inc. is a biotechnology company. The company is headquartered in Boston, MA. | Commercial Services |
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Technology |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Technology Services |
